Patents by Inventor Sujay Singh

Sujay Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090111754
    Abstract: The present invention provides cell permeable NF-?B inhibitors consist of a polypeptide derived from the p65 subunit of NF-?B and a protein transduction domain derived from antennapedia third helix sequence. The inhibitor suppressed NF-?B activation induced by TNF, LPS, IL-1, okadaic acid, PMA, H2O2 and cigarette smoke condensate. NF-?B-regulated reporter gene expression induced by TNF, TNFR1, TRADD, TRAF2, NIK, IKK and p65 was suppressed by the inhibitor. The inhibitor enhanced TNF- and chemotherapeutic agent-induced apoptosis. Overall these results demonstrate a NF-?B inhibitor that can selectively inhibit NF-?B activation induced by various inflammatory stimuli, down-regulate NF-?B mediated gene expression and upregulate apoptosis.
    Type: Application
    Filed: March 25, 2008
    Publication date: April 30, 2009
    Inventors: Bharat B. Aggarwal, Sujay Singh
  • Patent number: 7368430
    Abstract: The present invention provides cell permeable NF-?B inhibitors consist of a polypeptide derived from the p65 subunit of NF-?B and a protein transduction domain derived from antennapedia third helix sequence. The inhibitor suppressed NF-?B activation induced by TNF, LPS, IL-1, okadaic acid, PMA, H2O2 and cigarette smoke condensate. NF-?B-regulated reporter gene expression induced by TNF, TNFR1, TRADD, TRAF2, NIK, IKK and p65 was suppressed by the inhibitor. The inhibitor enhanced TNF- and chemotherapeutic agent-induced apoptosis. Overall these results demonstrate a NF-?B inhibitor that can selectively inhibit NF-?B activation induced by various inflammatory stimuli, downregulate NF-?B mediated gene expression and upregulate apoptosis.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: May 6, 2008
    Assignee: Research Development Foundation
    Inventors: Bharat B. Aggarwal, Sujay Singh
  • Patent number: 6998383
    Abstract: The present invention provides a RANK (receptor activator of NF-?B) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The peptide inhibitor inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: February 14, 2006
    Assignee: Research Development Corporation
    Inventors: Bharat Aggarwal, Bryant G. Darnay, Sujay Singh
  • Publication number: 20050201976
    Abstract: The present invention provides cell permeable NF-?B inhibitors consist of a polypeptide derived from the p65 subunit of NF-?B and a protein transduction domain derived from antennapedia third helix sequence. The inhibitor suppressed NF-?B activation induced by TNF, LPS, IL-1, okadaic acid, PMA, H2O2 and cigarette smoke condensate. NF-?B-regulated reporter gene expression induced by TNF, TNFR1, TRADD, TRAF2, NIK, IKK and p65 was suppressed by the inhibitor. The inhibitor enhanced TNF- and chemotherapeutic agent-induced apoptosis. Overall these results demonstrate a NF-?B inhibitor that can selectively inhibit NF-?B activation induced by various inflammatory stimuli, downregulate NF-?B mediated gene expression and upregulate apoptosis.
    Type: Application
    Filed: November 4, 2004
    Publication date: September 15, 2005
    Inventors: Bharat Aggarwal, Sujay Singh
  • Publication number: 20040250307
    Abstract: The present invention provides methods for producing exogenous and chimeric antibodies in avians. One aspect of the present invention is a method of producing avians or avian cells lacking endogenous immunoglobulin light chain and heavy chain loci, or portions thereof, and having at least a portion of at least one exogenous immunoglobulin locus. The present invention provides a method for obtaining an avian cell with a deletion in an endogenous immunoglobulin locus by by introducing a targeting construct comprising two regions of sequences which are homologous to the 5′ and 3′ flanking sequences of the region to be deleted in the wild-type locus. In addition, the invention provides methods for inserting exogenous immunoglobulin gene loci into the genome of an avian cell. A second aspect of the invention is the generation of transgenic avian species or transgenic avian cells for producing chimeric antibodies.
    Type: Application
    Filed: December 9, 2003
    Publication date: December 9, 2004
    Inventors: Sujay Singh, Peter Dias
  • Publication number: 20040167072
    Abstract: The present invention provides a RANK (receptor activator of NF-&kgr;B) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The decoy peptide inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
    Type: Application
    Filed: February 25, 2004
    Publication date: August 26, 2004
    Inventors: Bharat B. Aggarwal, Bryant G. Darnay, Sujay Singh
  • Publication number: 20040098756
    Abstract: The present invention concerns transgenic vertebrates that are useful in expressing proteins and in producing antibodies. The present invention discloses methods for producing vertebrates that are transgenic for a bacteriophage RNA polymerase. The present invention further discloses methods for the use of such transgenic vertebrates in protein expression and in antibody production.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 20, 2004
    Inventor: Sujay Singh
  • Patent number: 6623936
    Abstract: A method for diagnosing clinically distinct embryonal and alveolar subtypes of rhabdomyosarcoma, including contacting a reagent including an antibody that specifically binds myogenin with a sample that includes at least one rhabdomyosarcoma cell or at least one extract of at least one rhabdomyosarcoma cell, detecting the binding of the antibody to the sample to determine the presence, absence, or amount of myogenin in the sample, and diagnosing clinically distinct embryonal and alveolar subtypes of rhabdomyosarcoma, alveolar rhabdomyosarcoma having an increased amount of binding as compared to embryonal rhabdomyosarcoma.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: September 23, 2003
    Assignee: Imgenex
    Inventors: Peter Dias, Sujay Singh
  • Publication number: 20030013170
    Abstract: The present invention provides a RANK (receptor activator of NF-&kgr;B) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The peptide inhibitor inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
    Type: Application
    Filed: May 10, 2002
    Publication date: January 16, 2003
    Inventors: Bharat Aggarwal, Bryant G. Darnay, Sujay Singh
  • Publication number: 20020028488
    Abstract: The present invention provides methods for producing exogenous and chimeric antibodies in avians. One aspect of the present invention is a method of producing avians or avian cells lacking endogenous immunoglobulin light chain and heavy chain loci, or portions thereof, and having at least a portion of at least one exogenous immunoglobulin locus. The present invention provides a method for obtaining an avian cell with a deletion in an endogenous immunoglobulin locus by by introducing a targeting construct comprising two regions of sequences which are homologous to the 5′ and 3′ flanking sequences of the region to be deleted in the wild-type locus. In addition, the invention provides methods for inserting exogenous immunoglobulin gene loci into the genome of an avian cell. A second aspect of the invention is the generation of transgenic avian species or transgenic avian cells for producing chimeric antibodies.
    Type: Application
    Filed: June 18, 2001
    Publication date: March 7, 2002
    Inventors: Sujay Singh, Peter Dias